Biotechnology
CARsgen Presents Updated Research Results on Zevor-cel at 2023 ASH Annual Meeting
SHANGHAI, Dec. 12, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the 2023 American Society of Hematology ("ASH") Annual Meetin...
2023-12-12 21:50
1653
The NDA for New Indication of Henlius Anti-PD-1 mAb Serplulimab in Combination with Chemotherapy for the First-line Treatment of non-squamous NSCLC Accepted by the NMPA
SHANGHAI, Dec. 12, 2023 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the NDA for new indication of HANSIZHUANG, serplulimab, an innovative anti-PD-1 mAb independently developed by the company, in combination with chemotherapy as a first-line treatment for patients with...
2023-12-12 20:30
2206
KOSMODE HEALTH SINGAPORE PTE LTD, CLINCHES "THE MOST TRANSFORMATIONAL COLLABORATION" 2023 SICC AWARDS IN PARTNERSHIP WITH NESTLÉ SINGAPORE AND NESTLÉ R&D CENTRE.
Achieving functional food security that is good for health of the people and
health of the earth
SINGAPORE, Dec. 12, 2023 /PRNewswire/ -- KosmodeHealth Singapore
2023-12-12 20:00
1958
Dizal Impresses with Its Differentiated Hematological Oncology Portfolio at 2023 ASH
SHANGHAI, Dec. 12, 2023 /PRNewswire/ -- Dizal presented compelling data from its robust portfolio of hematological oncology at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition held inSan Diego, California from December 9-12. The data showcased updated results of Dizal's ...
2023-12-12 18:00
1609
Illumina partners with HaploX to build a domestically produced flagship benchtop sequencing system
SHENZHEN, China, Dec. 12, 2023 /PRNewswire/ -- On December 9, Illumina, a global leader in DNA sequencing and array-based technologies, and HaploX, aChina -based high-tech company specializing in oncology liquid biopsy and genetic big data, jointly announced the official launch of the first NextSe...
2023-12-12 17:31
2424
WuXi Biologics Named to 2023 Dow Jones Sustainability World Index
* Identified as a global sustainability leader by S&P Global * Committed to generating long-term value for all stakeholders SHANGHAI, Dec. 12, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), an...
2023-12-12 17:00
2425
MGI Wraps Up Inaugural the Future of Omics Research Summit
DUBAI, UAE, Dec. 11, 2023 /PRNewswire/ -- MGI, a company committed to building core tools and technology to lead life science, recently concluded its inaugural The Future of Omics Research Summit, the global event focused on the field of population genomics, metagenomics research and precision me...
2023-12-12 11:09
1296
Qilu Pharmaceutical Announces Results from Phase I Clinical Study for Its Novel Bispecific Antibody QLS31905 at ESMO Immuno-Oncology Congress
JINAN, China, Dec. 12, 2023 /PRNewswire/ -- During the ESMO Immuno-Oncology Congress 2023 held inGeneva, Switzerland, from December 6th to 8th, Qilu Pharmaceutical presented the latest results of the Phase I clinical trial for QLS31905 in patients with advanced solid tumors through a poster prese...
2023-12-12 11:04
1936
Live from ASH 2023 | Ascentage Pharma Presents the First Dataset of Bcl-2 inhibitor Lisaftoclax in Patients with AML, Demonstrating Favorable Efficacy and Safety
SUZHOU, China and ROCKVILLE, Md., Dec. 11, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released the results of lisaftoclax (A...
2023-12-12 09:41
2394
IASO Bio and Innovent Present New Data of FUCASO® (Equecabtagene Autoleucel) for Multiple Myeloma Patients in Oral Presentation at ASH 2023
SHANGHAI and NANJING, China and SAN JOSE, Calif., Dec. 11, 2023 /PRNewswire/ -- IASO biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, and Innovent Biologics, Inc. ("Innovent", H...
2023-12-12 03:30
1570
Menarini Group Presented Initial Safety and Efficacy Data from Phase 1b/2 ELEVATE and ELECTRA Combination Studies of ORSERDU® (Elacestrant) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2023 San Antonio Breast Cancer Symposium
* ELEVATE and ELECTRA studies were designed with the objective to overcome different treatment resistance mechanisms and enhance patient outcomes with oral-oral combination options. * A preliminary analysis of data in the phase 1b part of the ELEVATE trial demonstrates antitumor activity of t...
2023-12-12 00:42
2745
Lunit Advances to Stage 2 of Australia's National Breast Cancer Screening Project
* After a successful stage 1, Lunit INSIGHT MMG moves to prospective validation inAustralia's BreastScreen NSW Machine Reading Solution Project SEOUL, South Korea, Dec. 11, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therape...
2023-12-11 22:30
1749
Yingli Pharma presents a pivotal Phase 2 study data evaluating linperlisib in relapsed or refractory peripheral T-cell lymphoma in an oral session at the American Society of Hematology 2023 Annual Meeting
Linperlisib achieved Overall Response Rate of 48% with 30% being Complete Response and manageable safety profile in the r/r PTCL phase 2 study SHANGHAI and SAN FRANCISCO, Dec. 11, 2023 /PRNewswire/ -- Shanghai Yingli Pharmaceutical Co., Ltd. ("Yingli Pharma"), a biopharmaceutical company focused ...
2023-12-11 21:00
1516
Mabwell Announces the CDE Approval of Novel Nectin-4 Targeting ADC for Phase III Clinical Trial
SHANGHAI, Dec. 11, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its submission to the Center for Drug Evaluation (CDE) of the National Medical Products Administration for the "A Randomized, Open-label, Controlled, Mu...
2023-12-11 20:00
1324
HanAll Biopharma's Partner, NurrOn Pharmaceuticals Incorporated Appoints Dr. Almira Chabi, MD, EGMP to Board of Directors
WOBURN, Mass., Dec. 11, 2023 /PRNewswire/ -- HanAll Biopharma's partner NurrOn Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of Parkinson's disease (PD) and other Nurr1-related human disorders, is pleased to...
2023-12-11 20:00
1511
First Patient Dosed in U.S. Expanded Access Program for TLX250-CDx, Telix's Breakthrough Kidney Cancer Imaging Agent
MELBOURNE, Australia and INDIANAPOLIS, Dec. 11, 2023 /PRNewswire/ -- Telix
Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the
first patient has been dosed in aUnited States (U.S.) expanded access program
(EAP, ClinicalTrials.gov ID:NCT06090331
2023-12-11 19:40
1458
Hummingbird Bioscience Strengthens Leadership Team with Appointment of Angèle Maki as Chief Business Officer
SAN FRANCISCO and SINGAPORE, Dec. 11, 2023 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced the appointment of Angèle Maki, Ph.D., as Chief Business Offi...
2023-12-11 18:00
1633
Live from ASH 2023 | Ascentage Pharma Presents Updated Data from US Study of Olverembatinib, Further Validating Encouraging Efficacy in Patients Resistant to Ponatinib or Asciminib
SUZHOU, China, and ROCKVILLE, Md., Dec. 10, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated data from a US study ...
2023-12-11 13:30
1368
Live from ASH 2023 | Ascentage Pharma Releases Encouraging Long-Term Data of Bcl-2 Inhibitor Lisaftoclax in R/R CLL, Including an ORR of 73.3%
SUZHOU, China and ROCKVILLE, Md., Dec. 10, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released the latest efficacy and safety...
2023-12-11 13:14
1400
MGI Expands Presence in Latin America with New Partnerships with Genos Médica and TCL Group
SAO PAULO, Dec. 10, 2023 /PRNewswire/ -- MGI Tech Co. Ltd., a company committed to building core tools and technology to lead life science, today announced partnerships with Genos Médica, aMexico-based specialized center in genomics, and TCL Group, a company dedicated to the import and sales of l...
2023-12-11 11:26
1513
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
6801
